Clinical Trial Search

Phase 3 N=222 Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.09; -0.93 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 5.4% serious AE View details

Phase 3 N=405 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin

Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) — 77.1; 83.8 Percentage of participants

Eisai Co., Ltd. Results Nov 2015 15.6% serious AE View details

Phase 3 N=237 Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Primary: Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26 — 31.7; 88.4 Percentage of Participants

Eisai Inc. Results Nov 2015 1.8% serious AE View details

Phase 3 N=456 Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Diabetes · Diabetes Mellitus, Type 1

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment — -0.73; -0.65 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 10.4% serious AE View details

Phase 3 N=10,275 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue · Dengue Fever · Dengue Hemorrhagic Fever

Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD…

Sanofi Pasteur, a Sanofi Company Results Nov 2015 14.6% serious AE View details

Phase 3 N=191 Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

Chronic Myelogenous Leukemia

Primary: Percentage of Participants With Complete Cytogenetic Response (CCyR) — 50.0; 42.1 Percentage of participants — p=0.3106

Novartis Pharmaceuticals Results Nov 2015 9.7% serious AE View details

Phase 3 N=40 A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

Diabetes · Diabetes Mellitus, Type 2

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — 0.05; -0.49 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 10.0% serious AE View details

Phase 3 N=460 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.30; -1.32 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 5.5% serious AE View details

Phase 3 N=1,006 Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment — -1.17; -1.29 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 19.1% serious AE View details

Phase 3 N=1,030 Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment — -1.06; -1.19 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 15.4% serious AE View details

Phase 3 N=687 Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.28; -1.07; -1.26 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 2.6% serious AE View details

Phase 3 N=435 Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.24; -1.35 percentage of glycosylated haemoglobin

Novo Nordisk A/S Results Nov 2015 3.7% serious AE View details

Phase 3 N=252 OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

Kidney Transplantation

Primary: Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12 — 24.2; 19.8 percentage…

Hoffmann-La Roche Results Nov 2015 79.4% serious AE View details

Phase 3 N=329 A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Disease, Hodgkin

Primary: Progression-free Survival by Independent Review — 42.9; 24.1 months — p=0.001

Seagen Inc. Results Nov 2015 19.6% serious AE View details

Phase 3 N=1,588 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease · Meningococcal Meningitis

Primary: Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously…

Novartis Vaccines Results Nov 2015 3.8% serious AE View details